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Autoimmune disorders during pregnancy are an established
cause of complications and mortality.1,2 Women without an
autoimmune disorder history, but with complications during
pregnancy, have a raised number of autoantibodies.3,4 This may
be due to exacerbation of an undiagnosed autoimmune
disorder or an unknown maternal immune reaction. It is not
known whether the occurrence of autoantibodies, which is
usually transient and limited to pregnancy and the immediate
postpartum period, is predictive of future immunological
disease.5
Some studies have found that antinuclear antibodies (ANAs)
occur more often in patients with pre-eclampsia, intrauterine
growth retardation, fetal death and placental abruption.6-8
Other studies, however, have not confirmed these results.9-11
Therefore, there is no consensus on the role of ANAs during
pregnancy. If the exact role of this disorder could be
established, it is possible that ANA determination may serve as
a prognostic factor for pregnancy outcome, and possibly also
influence therapy.
Patients and methods
Patients 
Sera from 408 consecutive pregnant patients admitted from
January 2001 to November 2001 at the high-risk obstetric unit
(HROU), Universitas Hospital, Bloemfontein, were tested for
the presence of ANAs. The patients were all admitted with
complications during pregnancy, including hypertensive
disorders, cardiac disease, diabetes mellitus and fetal
complications. Forty-six patients with a positive ANA
determination (11% of the total group) served as the study
group. The first 2 eligible patients with a negative ANA test
before and after a patient with a positive result were selected as
controls, and 92 control patients were included in the study. In
order to be included delivery must have taken place at the
Universitas Hospital and the ANA determination must have
been performed during pregnancy or within 48 hours after
delivery. Patients admitted postpartum were excluded.
Demographic data, obstetric history, reason for admission,
clinical and laboratory data and pregnancy outcome were
compared in the two groups. In case of a positive ANA test the
titre and pattern of the antibodies were determined, either
antinuclear or anticytoplasmic. In addition, anticardiolipin
(ACL) antibodies and HIV status were determined for all the
patients. Pregnancy outcome was determined and compared
between the two groups. A standard enquiry form was used to
collect data from all the patients’ records. The Ethics
Committee of the Faculty of Health Sciences, University of the
Free State approved the study.
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Objectives. To assess possible associations between the
presence of antinuclear antibodies (ANAs) and pregnancy
outcome in order to determine the significance of this test in
obstetric practice.
Methods. A case-control study was performed on 408 patients
admitted to an obstetric high care unit and on whom ANA
testing was consecutively performed. The study group
consisted of 46 patients who tested positive for ANAs and a
control group of 92 patients who tested negative for ANAs. In
addition to demographic data, indications for admission and
pregnancy outcome were compared between the two groups.
Results. Of the 46 patients with a positive ANA result, 28 had
an antinuclear pattern, 13 an anticytoplasmic pattern and 5 an
antinuclear and an anticytoplasmic pattern. No significant
differences were observed between the two groups (ANA-
positive and negative) with regard to demographic data,
indication for admission, clinical and laboratory data, and
pregnancy outcome. The patients were also tested for
anticardiolipin antibodies, and significantly more patients
with severe pre-eclampsia tested positive (24% versus 4.7%, 
p = 0.01). No difference in HIV status and presence of
autoantibodies was found between the two groups.
Conclusion. The presence of ANAs was not associated with
adverse pregnancy outcome. Therefore routine patient testing
for ANAs in an obstetric high-care unit is not recommended.
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Definitions 
Complications in pregnancy outcome were defined as relevant
complications during pregnancy subsequent to admission. If the
reason for admission remained relevant or caused complications
during the course of the pregnancy it was also considered a
complication in pregnancy outcome.
Gestational age at time of ANA determination and delivery
was determined by dates of last normal menses. In case this
determination differed from ultrasound dating by more than 
1 - 3 weeks in the first, second or third trimester respectively, the
ultrasonographic dating was used to determine the gestational
age.
Miscarriage was defined as fetal birth weight below 500 g,
and neonatal death as death in the first 28 days of life.
Intrauterine growth restriction (IUGR) was defined as a
gestational age-controlled birth weight below the 10th percentile.
Preterm labour  was diagnosed if spontaneous labour
occurred before 37 weeks of gestation, with a fetal birth weight
of 500 g or more. Preterm rupture of membranes (PROM) was
defined as spontaneous rupture of membranes before the onset
of labour when this occurred before a gestational  age of 37
weeks and the birth weight was at least 500 g. Oligohydramnios
was defined as an amniotic fluid index less than 5 on sonar, and
poor obstetric history was defined as repetitive reproductive
failure.
Hypertensive disorders were defined as a systolic blood
pressure (SBP) of 140 mmHg or more or a diastolic blood
pressure (DBP) of 90 mmHg or more. Gestational hypertension
was defined as a rise in BP as described above without
proteinuria. Pre-eclampsia was diagnosed in case of a SBP of 140
mmHg or more or a DBP of 90 mmHg or more in combination
with proteinuria of at least 0.3 g/24 h. The presence of one or
more of the following signs or symptoms indicated that the pre-
eclampsia was severe: SBP 160 mmHg or DBP 110 mmHg or
more, proteinuria of at least 5 g/24 h or 3+ or more with the
dipstick method, oliguria (urinary volume of < 400 ml/24 h),
cerebral or visual disturbances, cyanosis or pulmonary oedema.
The diagnosis of chronic hypertension was based on a history of
hypertension before pregnancy or before 20 weeks’ gestation.
Superimposed pre-eclampsia was diagnosed as a combination of
chronic hypertension and pre-eclampsia.
Cardiac failure was diagnosed in cases of clinical pulmonary
oedema and respiratory failure if patients had to be ventilated.
Thromboembolism included deep-vein thrombosis (DVT),
pulmonary embolism and sinus cavernosus thrombosis
diagnosed with radiological confirmation. 
Laboratory measurements
Proteinuria was quantified by 24-hour urine collection or with a
semiquantitative assessment using a standard dipstick method.
Liver and renal function parameters were determined using a
standard hospital autoanalyser. Liver enzyme abnormalities
were defined as alanine aminotransferase (ALAT) ≥ 75 IU/l.
Haemolysis was defined as lactate dehydrogenase (LDH) ≥ 600
IU/l in combination with anaemia with red cell fragments. Total
platelet concentrations were established using a Technicon H1
blood cell analyser. Thrombocytopenia was defined as platelet
count < 150 x 109/l. Coagulopathy was diagnosed when the
whole-blood clotting time was ≥ 8 minutes.
The Enzygnost HIV Integral test (Dade Behring, Marburg) and
the Vironostika HIV Uniform II Ag/Ab test (Organon Teknika,
Boxtel) were used in a parallel test to determine HIV status. In
order to test positive both test results had to be positive. If the
test results differed a new parallel test was performed on a new
sample. The CD4+ cell counts were determined by flow
cytometry using the MultiTEST CD3 FITC/CD8 PE CD45
PerCP/CD4 APC reagent (Becton Dickinson, San Jose).
The QUANTA Lite (INOVA Diagnostics, San Diego) was used
for immunological studies. ANAs were assayed by indirect
immunofluorescence on smears of HEp-2 cells. The different
dilutions were incubated with phosphate-buffered saline
solution for 30 minutes at room temperature. Fluorescein-
conjugated goat monovalent antiserum against human
immunoglobulin G (IgG) was the second antibody. The results
were given in serum dilutions. The threshold for positive was
established at 1:40, and any positive serum was then titrated by
successive dilutions until extinction of fluorescence. If the test
was positive the pattern was determined. In case of a
cytoplasmic pattern the threshold for positive was established at
1:10.
IgG and IgM ACL antibodies were quantified in serum using
an enzyme-linked immunosorbent assay (ELISA). The upper
limit of normal was set more than 5 standard deviations (SDs)
above mean at 15 GPL or 12.5 MPL. Values ranging from 15 to
25 GPL or 12.5 to 25 MPL were considered intermediate. Values
above 25 GPL or MPL were considered positive. If the value of
IgG or IgM or both was indeterminate the ACL test was
considered indeterminate. When both values were negative the
test was considered negative.
Statistical analysis
Results are given as median values with quartiles or as N (%). To
test for statistical associations between categorical variables the
chi-squared test was used. However, in case of an expected cell
size < 5 the Fisher’s exact test was used instead of the chi-
squared test. Numerical variables were compared using the
Mann-Whitney test. A p-value < 0.05 was considered statistically
significant and 95% confidence intervals (CIs) were calculated
for differences in medians and percentages.
Results
The study group comprised 46 ANA-positive patients and the
control group 92 ANA-negative patients. No patients had a
history of autoimmune disease.
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The study group included 28 patients with an antinuclear
pattern, 13 with an anticytoplasmic pattern and 5 with an
antinuclear and an anticytoplasmic pattern (Table I). Four
patients had two different antinuclear patterns. With regard to
antinuclear patterns, a speckled pattern was found in 20 patients
(60.6%), a nucleolar pattern in 8 (24.2%), and a homogeneous
pattern in 7 (21.2%). Scl70 and lysosomal antibodies were found
in 1 patient (3.0%). With regard to anticytoplasmic patterns, all
patients had a smooth muscle pattern and 1 patient had two
patterns (smooth muscle and parietal cell).
Demographic, reproductive and clinical data, as well as
reasons for admission, are described in Table II. Age, gravidity,
obstetric history and gestational age at ANA determination and
at delivery did not differ significantly between the study and
control groups. Primigravidas were equally distributed between
the study and control groups. No significant differences between
the two groups were found for presence of chronic hypertension
or for BP level on admission. BP levels were, however, slightly
higher in the control group (statistically not significant).
The main reasons for admission were hypertensive disorders,
cardiac disease, preterm labour, PROM, congenital
malformations and poor obstetric history. There was no
statistical difference between the two groups. Drugs known to
induce ANAs, namely methyldopa and hydralazine, were
equally distributed between the study and control groups (43.5%
and 42.4% respectively).
Both groups were tested for ACL antibodies. Significantly
more negative ACL tests were found in the control group than in
the study group (54.4% versus 34.9%, p = 0.03).
Table II. Demographic, reproductive and clinical data according to ANA determination. Data are presented as median (quartiles)  
ANA determination
Positive (N = 46)* Negative (N = 92)*
(study group) (control group) p-value 95% CI for differences
Mean age (yrs) 26.5 28.5 0.80 -2, 3
Obstetric indices
Mean gravidity 2.5 2.5 0.95 -1, 1
Primigravida (%) 2.83 26.1 0.79 -13.1, 18.2
Reproductive failure (%)† 36.4 41.2 0.64 -19.4, 11.8
Hypertension during pregnancy (%)‡ 34.6 37.3 0.81 -18.0, 10.7
GA at ANA determination (weeks) 30 (26.0 - 35.0) 30 (27.0 - 32.5) 0.75 -3, 2
GA at delivery (weeks) 32 (28.0 - 38.0) 32 (30.0 - 36.0) 0.89 -2, 2
Clinical indices
Chronic hypertension (%) 8.7 10.9 0.77 -11.8, 9.2
Mean systolic blood pressure 138.0 150.0 0.07 0, 2
Mean diastolic blood pressure 80.0 84.0 0.37 -4, 10
Main reasons for admission
Hypertensive disorder (%) 50.0 58.7 0.33 -25.9, 8.8
Cardiac disease (%) 10.9 9.8 1.00 -9.1, 12.8
Preterm labour (%) 8.7 5.4 0.48 -5.6, 13.6
PROM (%) 2.2 4.4 0.66 -7.8, 5.4
Congenital malformations (%) 4.4 3.3 1.00 -5.5, 9.4
Poor obstetric history (%) 6.5 8.7 0.75 10.7, 8.2
GA = gestational age; PROM = pre-term rupture of membranes.
*The interquartile range or percentage is given in brackets.
†Reproductive failure = the occurrence of a miscarriage, fetal loss, ectopic pregnancy or neonatal death in the obstetric history (excluding primigravida).
‡Hypertension during pregnancy = hypertension during pregnancy in the obstetric history (excluding primigravida).
Table I. Titre and pattern in case of a positive ANA determination
Antinuclear (N = 33) Anticytoplasmic (N = 18)
N % N %
Titre
1:20 - - 5 27.8
1:40 16 48.5 6 33.3
1:80 12 36.4 3 16.7
≥ 1:160 5 15.1 4 22.2
Pattern*
Speckled 20 60.6
Homogeneous 7 21.2
Nucleolar 8 24.2
Scl70 1 3.0
Lysosomal 1 3.0
Centromere 0 0.0
Mitotic spindle 0 0.0
PCNA 0 0.0
Nuclear membrane 0 0.0
Smooth muscle 18 100.0
Parietal cell 1 5.6
*Four patients had two different antinuclear patterns, 1 patient had two different
anticytoplasmic patterns and 5 patients had an antinuclear as well as an
anticytoplasmic pattern.
PCNA = proliferating cell nuclear antigen.
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Although not significant, more positive ACL tests were found
in the study group than in the control group (27.9% v. 14.4%, 
p = 0.06). There was no difference between the study and control
groups for positive IgG ACL measurements (14.0% v. 8.9%, 
p = 0.38) and IgM ACL measurements (16.3% v. 8.8%, 
p = 0.24). Furthermore, HIV status and CD4+ count were not
statistically different between the two groups.
Comparison of maternal pregnancy outcome between the
study and control groups is given in Table III. There was no
significant difference between the two groups for complications
such as severe pre-eclampsia, the HELLP syndrome (haemolysis,
elevated liver enzymes and low platelet count), eclampsia,
thromboembolism, respiratory complications, renal failure and
coagulopathy. There was 1 maternal death in the study group
and 2 in the control group (p = 1.00).
Fetal outcome was compared between the 51 newborns from
the study group and the 95 newborns in the control group (Table
IV). There were 5 twins in the study group and 3 in the control
group. No significant differences were found in the number of
miscarriages, fetal losses and complications after birth between
the two groups. The presence of major complications, including
neonatal death, did not differ significantly between the
newborns in the study and control groups.
There were no significant differences in admission to the
intensive care unit between the two groups (N = 17, 41.5% v. 
N = 38, 50.0%), p = 0.38). Newborns in the study group had a
slightly higher birth weight than newborns in the control group
(1 765.0 g v. 1 502.5 g), but this was not statistically significant (p
= 0.26). There was no significant difference in the study and
control groups for the presence of IUGR (14.9% v. 17.8%, p =
0.67), preterm labour (15.2% v. 12%, p = 0.59), PROM (8.7% v.
9.8%, p = 1.00) and oligohydramnios (15.2% v. 18.2%, p = 0.63).
Pregnancy outcome was compared for the ACL-positive and
negative patients. The ACL-positive patients experienced more
complications, but this was not statistically significant. Severe
pre-eclampsia, however, occurred significantly more often in the
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Table IV. Fetal outcome in relation to ANA determination of the mother
ANA determination
Positive (%) Negative (%)
(N = 51) (N = 95) 
(study group) (control group) p-value 95% CI for differences
Miscarriage 5.9 2.1 0.34 -3.0, 11.9
Fetal loss 13.7 20.0 0.22 -17.9, 6.9
Neonatal death 2.0 1.1 1.00 -3.5, 6.8
Discharge without complications 47.1 40.0 0.41 -9.7, 23.6
Discharge with complications 31.4 36.8 0.58 -20.2, 11.8
Table III. Maternal outcome in relation to ANA determination (median)
ANA determination
Positive (%) Negative (%)
(N = 46) (N = 92)
(study group) (control group) p-value 95% CI for differences
Discharge without complications 52.2 55.4 0.72 -20.6, 14.1
Discharge with complications 47.8 44.5 0.72 -14.1, 20.6
Hypertensive disorders 30.4 33.7 0.70 -19.0, 13.4
Severe pre-eclampsia 6.5 8.7 0.75 -10.7, 8.2
Thromboembolism 2.2 1.1 1.00 -3.6, 7.6
Eclampsia 10.9 9.8 1.00 -9.1, 12.8
Pleural effusion 6.5 5.4 1.00 -6.9, 10.8
Respiratory failure 2.2 1.1 1.00 -3.6, 7.6
Cardiac failure 6.5 6.5 1.00 -8.2, 9.9
Creatinine > 200 µmol/l 0.0 7.6 0.10 -12.7, -0.3
Liver enzyme abnormalities 4.4 9.8 0.36 -13.2, 4.4
Thrombocytopenia 15.2 19.6 0.53 -16.7, 9.6
Haemolysis 8.7 15.2 0.20 -16.7, 5.5
Placental abruption 8.7 7.6 1.00 -8.1, 11.9
Coagulopathy 2.2 4.4 0.66 -7.8, 5.4
Death 2.2 2.2 1.00 -5.0, 6.9
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ACL-positive than the ACL-negative patients (24.0% v. 4.7%, p =
0.01). There was a tendency to more thrombocytopenia among
ACL-positive than ACL-negative patients, but this was also not
statistically significant (28.0% v. 14.1%, p = 0.14).
No significant differences were found when comparing HIV-
positive and negative patients. Three maternal deaths (3.2%)
occurred in the HIV-negative group and none in the positive
group (p = 0.57). A low platelet count was present in 9 HIV-
positive patients (26.5%) compared with 9 HIV-negative patients
(15.0%, p = 0.13).
Discussion
No consensus exists on the association between autoantibodies
and complications during pregnancy or a poor pregnancy
outcome. Several authors have described a positive association
between ANAs and adverse pregnancy outcome, while others
could not confirm such an association. Iijima et al.7 observed that
a significantly higher rate of spontaneous abortion was observed
in ANA-positive subjects. However, they found that ANAs did
not affect the rates of preterm delivery, stillbirth, pregnancy-
induced hypertension, malformation, or gender ratio. Kiuttu et
al.6 demonstrated a raised number of stillbirths in ANA-positive
women. An association between the presence of ANAs and pre-
eclampsia was found by Matthiesen et al.8 However, in the study
by Patton et al.11 the presence of autoantibodies in subjects
without a documented autoimmune disease did not appear to
have an adverse effect on maternal or fetal well-being. Similar
results were reported by El-Roeiy et al.10 They suggested that
autoantibody abnormalities (phospholipids, histones,
polynucleotides) after 16 weeks’ gestation and at low titres may
have no major adverse effects of pregnancy outcome and may
not require treatment. Incerpi et al.9 found no relationship
between explained or unexplained fetal death and a positive
ANA determination and no significant association between
ANA titres or patterns and fetal outcome.
The purpose of this study was to compare the pregnancy
outcome of obstetric patients with a positive ANA determination
with that of patients with a negative test, and to determine if the
presence of ANA was related to adverse pregnancy outcome.
Comparison of the study and control group was justified
because the demographic data, obstetric  history and reasons for
admission did not differ significantly between the two groups.
In this study, no association was found between the presence of
ANA and adverse pregnancy outcome. This finding suggests
that ANAs were not responsible for complications during
pregnancy in patients without a documented autoimmune
disease. This applies especially to hypertensive disorders,
including pre-eclampsia. Contrary to our expectations a
tendency was observed to more HELLP syndrome and renal
insufficiency in the ANA-negative group, although this was not
statistically significant (Table III). This finding correlated with
slightly higher median BP in this group (Table II).
This study population consisted of women with extremely
complicated pregnancies who were referred to a tertiary
referral centre. As this was the only tertiary referral centre for a
large area in central South Africa, it is unlikely that patients
with similar complications had been referred to another centre.
Nevertheless, since these patients were highly selected, they do
not represent the obstetric population as a whole and a
selection bias was possible. The limited data in some of the
categories could have introduced a beta error and the results
have to be interpreted against this background. The only
reassuring factor was the similarity in demographic data
between the study and control groups.
The control group often tested negative for ACL, with the
study group more positive, although the difference was not
statistically significant. An explanation for this observation
could be that stimulation of the immune system caused
elevation of different autoantibodies. Some studies have
suggested that autoantibodies occurred more often in HIV-
infected patients, possibly because of B-cell stimulation. 12,13
However this was not confirmed in the present study.
When comparing the pregnancy outcome of the ACL-
positive and negative patients, twice as many ACL-positive
patients presented with severe pre-eclampsia (p = 0.01). This
finding was consistent with previous reports by Kilpatrick14
and Branch et al.15 ACL antibodies have been associated with a
predisposition to arterial and venous thrombosis. It is possible
that these autoantibodies account for some of the placental
damage seen in hypertensive disorders.4,16 It was remarkable
that reproductive failure in the obstetric history did not differ
significantly between the ACL-positive and negative patients,
since ACL antibodies are known to cause reproductive
failure.17,18 These results must, however, be used with caution,
because there was a large intra-patient variation on test results
over time.19
This study could not confirm an association between ANA
and an adverse pregnancy outcome. Unless the patient
presents with a history or symptoms suggesting an
autoimmune disease, ANA testing is unlikely to contribute
towards the diagnosis or management of the patient.
We acknowledge the valuable input of Cornel van Rooyen
(biostatistician), Lucas Kapsenberg (research assistant), and Ina
Venter, who prepared the manuscript.
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